DBPR112
DBPR112 is an orally bioavailable furanopyrimidine inhibitor targeting the EGFR ATP-binding site, demonstrating potent activity against wild-type (IC50=15 nM) and L858R/T790M mutant (IC50=48 nM) forms. It has shown significant antitumor efficacy in preclinical research models, supporting its investigation in oncology studies for EGFR-driven cancers.
Product Specifications
CAS Number
1226549-49-0
Product Name Alternative
DBPR112, DBPR-112, DBPR 112, EGFR (wt), EGFR (L858R/T790M), EGFRL858R/T790M, EGFRWT
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.29% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (9.37 mM) ; DMSO:225 mg/mL (421.65 mM)
Smiles
CN (C) C\C=C\C (=O) Nc1cccc (c1) -c1c (oc2ncnc (N[C@H] (CO) c3ccccc3) c12) -c1ccccc1
Molecular Formula
C32H31N5O3
Molecular Weight
533.62
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog
Batf3 Rat shRNA Lentiviral Particle (Locus ID 60462)
